vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $80.1M, roughly 1.1× AMERISAFE INC). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 10.3%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 2.8%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
AMSF vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $86.8M |
| Net Profit | $8.1M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 10.2% | — |
| Revenue YoY | 10.3% | 17.7% |
| Net Profit YoY | -9.0% | — |
| EPS (diluted) | $0.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $86.8M | ||
| Q3 25 | $82.0M | $67.5M | ||
| Q2 25 | $81.1M | $60.0M | ||
| Q1 25 | $72.6M | $49.3M | ||
| Q4 24 | $74.0M | $73.7M | ||
| Q3 24 | $78.7M | $58.6M | ||
| Q2 24 | $75.8M | $31.1M |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | — | ||
| Q3 25 | $13.8M | $-91.3M | ||
| Q2 25 | $14.0M | $-111.7M | ||
| Q1 25 | $8.9M | $-116.2M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $14.3M | $-83.5M | ||
| Q2 24 | $11.0M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | -84.7% | ||
| Q3 25 | 21.3% | -140.7% | ||
| Q2 25 | 21.5% | -189.8% | ||
| Q1 25 | 15.5% | -245.8% | ||
| Q4 24 | 22.7% | -117.5% | ||
| Q3 24 | 22.6% | -152.1% | ||
| Q2 24 | 18.1% | -327.6% |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 16.9% | -135.3% | ||
| Q2 25 | 17.2% | -186.2% | ||
| Q1 25 | 12.3% | -235.5% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 18.2% | -142.7% | ||
| Q2 24 | 14.5% | -312.2% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | — | ||
| Q3 25 | $0.72 | — | ||
| Q2 25 | $0.73 | $-0.33 | ||
| Q1 25 | $0.47 | $-0.36 | ||
| Q4 24 | $0.69 | $-0.24 | ||
| Q3 24 | $0.75 | $-0.28 | ||
| Q2 24 | $0.57 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $698.6M |
| Total Assets | — | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $297.0M | ||
| Q3 25 | $54.7M | $300.8M | ||
| Q2 25 | $48.5M | $301.2M | ||
| Q1 25 | $44.8M | $359.7M | ||
| Q4 24 | $44.1M | $323.8M | ||
| Q3 24 | $63.7M | $397.5M | ||
| Q2 24 | $30.6M | $412.5M |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $698.6M | ||
| Q3 25 | $274.8M | $702.3M | ||
| Q2 25 | $265.6M | $698.5M | ||
| Q1 25 | $260.8M | $767.9M | ||
| Q4 24 | $257.3M | $710.4M | ||
| Q3 24 | $314.4M | $773.5M | ||
| Q2 24 | $301.0M | $768.5M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $913.2M | ||
| Q3 25 | $1.2B | $904.9M | ||
| Q2 25 | $1.2B | $907.4M | ||
| Q1 25 | $1.2B | $966.7M | ||
| Q4 24 | $1.2B | $910.4M | ||
| Q3 24 | $1.3B | $991.1M | ||
| Q2 24 | $1.2B | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $-52.6M | ||
| Q3 25 | $10.7M | $-78.7M | ||
| Q2 25 | $-8.4M | $-67.4M | ||
| Q1 25 | $-1.8M | $-103.7M | ||
| Q4 24 | $24.2M | $-73.3M | ||
| Q3 24 | $8.4M | $-59.0M | ||
| Q2 24 | $-2.6M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | $-61.9M | ||
| Q3 25 | $9.8M | $-89.5M | ||
| Q2 25 | $-9.5M | $-74.9M | ||
| Q1 25 | $-1.8M | $-109.9M | ||
| Q4 24 | $23.4M | $-77.5M | ||
| Q3 24 | $8.4M | $-61.3M | ||
| Q2 24 | $-2.6M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | -71.3% | ||
| Q3 25 | 11.9% | -132.7% | ||
| Q2 25 | -11.7% | -124.9% | ||
| Q1 25 | -2.5% | -222.8% | ||
| Q4 24 | 31.5% | -105.1% | ||
| Q3 24 | 10.7% | -104.6% | ||
| Q2 24 | -3.5% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 10.7% | ||
| Q3 25 | 1.1% | 16.1% | ||
| Q2 25 | 1.3% | 12.4% | ||
| Q1 25 | 0.0% | 12.6% | ||
| Q4 24 | 1.1% | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | 0.1% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMSF
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
